Live feed16:15:00·22dPRReleasevia QuantisnowAgilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction AdenocarcinomaByQuantisnow·Wall Street's wire, on your screen.A· Agilent Technologies Inc.Industrials
